These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29019159)

  • 21. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silibinin prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease via mitochondrial stabilization.
    Lee Y; Park HR; Chun HJ; Lee J
    J Neurosci Res; 2015 May; 93(5):755-65. PubMed ID: 25677261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
    Chan WS; Durairajan SS; Lu JH; Wang Y; Xie LX; Kum WF; Koo I; Yung KK; Li M
    Neurochem Int; 2009 Nov; 55(6):414-22. PubMed ID: 19409437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humulus japonicus Prevents Dopaminergic Neuron Death in 6-Hydroxydopamine-Induced Models of Parkinson's Disease.
    Ryu YK; Kang Y; Go J; Park HY; Noh JR; Kim YH; Hwang JH; Choi DH; Han SS; Oh WK; Lee CH; Kim KS
    J Med Food; 2017 Feb; 20(2):116-123. PubMed ID: 28146406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease.
    Ay M; Luo J; Langley M; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    J Neurochem; 2017 Jun; 141(5):766-782. PubMed ID: 28376279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 10 weeks low intensity treadmill exercise intervention ameliorates motor deficits and sustains muscle mass via decreasing oxidative damage and increasing mitochondria function in a rat model of Parkinson's disease.
    Tung YT; Liao YC; Yeh TH; Tsao SP; Chang CC; Shih WT; Huang HY
    Life Sci; 2024 Aug; 350():122733. PubMed ID: 38763432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intranasal insulin improves mitochondrial function and attenuates motor deficits in a rat 6-OHDA model of Parkinson's disease.
    Iravanpour F; Dargahi L; Rezaei M; Haghani M; Heidari R; Valian N; Ahmadiani A
    CNS Neurosci Ther; 2021 Mar; 27(3):308-319. PubMed ID: 33497031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apomorphine-induced differences in cortical and striatal EEG and their glutamatergic mediation in 6-hydroxydopamine-treated rats.
    Vorobyov V; Sengpiel F
    Exp Brain Res; 2008 Nov; 191(3):277-87. PubMed ID: 18682921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic/xenogeneic transplantation of peptide-labeled mitochondria in Parkinson's disease: restoration of mitochondria functions and attenuation of 6-hydroxydopamine-induced neurotoxicity.
    Chang JC; Wu SL; Liu KH; Chen YH; Chuang CS; Cheng FC; Su HL; Wei YH; Kuo SJ; Liu CS
    Transl Res; 2016 Apr; 170():40-56.e3. PubMed ID: 26730494
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Martins IK; de Carvalho NR; Macedo GE; Rodrigues NR; Ziech CC; Vinadé L; Filho VMB; Menezes IA; Franco J; Posser T
    Oxid Med Cell Longev; 2018; 2018():2131895. PubMed ID: 30510616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Purinergic Antagonism Prevents Mitochondrial Dysfunction and Behavioral Deficits Associated with Dopaminergic Toxicity Induced by 6-OHDA in Rats.
    Kumar S; Mishra A; Krishnamurthy S
    Neurochem Res; 2017 Dec; 42(12):3414-3430. PubMed ID: 28836128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Live imaging of mitochondrial dynamics in CNS dopaminergic neurons in vivo demonstrates early reversal of mitochondrial transport following MPP(+) exposure.
    Dukes AA; Bai Q; Van Laar VS; Zhou Y; Ilin V; David CN; Agim ZS; Bonkowsky JL; Cannon JR; Watkins SC; Croix CM; Burton EA; Berman SB
    Neurobiol Dis; 2016 Nov; 95():238-49. PubMed ID: 27452482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells.
    Manáková S; Singh A; Kääriäinen T; Taari H; Kulkarni SK; Männistö PT
    Brain Res; 2005 Mar; 1038(1):83-91. PubMed ID: 15748876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease.
    Vernon AC; Palmer S; Datla KP; Zbarsky V; Croucher MJ; Dexter DT
    Eur J Neurosci; 2005 Oct; 22(7):1799-806. PubMed ID: 16197521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
    Coune PG; Bensadoun JC; Aebischer P; Schneider BL
    J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phloroglucinol attenuates motor functional deficits in an animal model of Parkinson's disease by enhancing Nrf2 activity.
    Ryu J; Zhang R; Hong BH; Yang EJ; Kang KA; Choi M; Kim KC; Noh SJ; Kim HS; Lee NH; Hyun JW; Kim HS
    PLoS One; 2013; 8(8):e71178. PubMed ID: 23976995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats.
    Jin F; Wu Q; Lu YF; Gong QH; Shi JS
    Eur J Pharmacol; 2008 Dec; 600(1-3):78-82. PubMed ID: 18940189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. α-Arbutin Protects Against Parkinson's Disease-Associated Mitochondrial Dysfunction In Vitro and In Vivo.
    Ding Y; Kong D; Zhou T; Yang ND; Xin C; Xu J; Wang Q; Zhang H; Wu Q; Lu X; Lim K; Ma B; Zhang C; Li L; Huang W
    Neuromolecular Med; 2020 Mar; 22(1):56-67. PubMed ID: 31401719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.